Hematology And Oncology Billing And Coding
Hematology and Oncology Governance Built for Multi-Modality Treatment Complexity
Oncology billing generates the largest claim denials in healthcare. A single chemotherapy regimen spans infusion codes (96400-96549), therapeutic drug codes, waste allowance calculations, and treatment plan substantiation. When a practice bills a 3-drug combination on the same day, clinicians expect all three drugs billed separately, while payers expect consolidated infusion times with documented start/stop intervals. When these align differently, claims are denied at 14-18% rates. Drug waste billing creates additional exposure when practices bill waste allowances that exceed plan limits, triggering recoupment demands months later. Radiation therapy coordination adds another layer when determining whether a radiation oncologist’s treatment planning code bundles into the medical oncologist’s visit versus billing separately, creating inconsistent revenue capture.
QWay Healthcare deploys certified oncology coders embedded in pre-submission workflow, armed with AI-governed validation rules tuned to major payer billing policies for each drug class. Our real-time monitoring flags high-cost infusion claims before submission, cross-references documented drug administration time against coded infusion intervals, and alerts practices when waste allowance calculations exceed plan-specific thresholds. For chemotherapy regimens, our system reconciles the treatment plan documentation against the specific drugs billed, automatically detecting misalignment between prescribed protocols and submitted claims.
The Financial Impact of Hematology and Oncology Billing Variance
Oncology practices billing $8M to $15M annually face material revenue volatility from coding errors.
A 250-patient active chemotherapy census at $32K average treatment cost generates $8M annual infusion revenue, with denial rates of 12-16% translating to $960K-$1.28M annual exposure.
Drug waste recoupment claims alone create $50K-$200K unrecovered exposure.
Practices implementing governance controls reduce oncology claim denials to 3-5%, recovering $600K-$1M annually, with treatment plan documentation improving accuracy by 28-35% and concurrent therapy compliance preventing $80K-$160K in annual bundling penalties.
Industry Benchmarks for Hematology and Oncology Billing Performance
Stable organizations operate within these ranges:
Claim denial rate: under 5%
Clean claim rate on first submission: 88 to 95%
Chemotherapy infusion coding accuracy: 92 to 97%
Accounts receivable days: under 45
Drug waste recoupment accuracy: 98 to 100%
Where the Problem Starts
Infusion time documentation often lacks precision
Clinicians record treatment start without documenting start time, stop time, or intervals between multiple drugs on the same date. Billing staff assigns infusion codes based on assumptions rather than documented facts.
Drug waste billing operates without governance
As most practices bill waste allowances routinely, following local precedent or partially understood payer guidelines. When a practice bills waste without verification, recoupment audits uncover hundreds of thousands in overbilling.
Multi-modality treatment introduces unchecked bundling decisions when patients receive concurrent chemotherapy and radiation therapy
Without governance controls, practices bill both specialties without required documentation, and payers then bundle the secondary claim entirely.
How QWay Healthcare Controls Hematology and Oncology Billing and Coding
Chemotherapy Infusion Time Reconciliation
Our AI-governed system cross-references treatment plan documentation against submitted infusion codes to verify time intervals match documented drug administration.
Treatment Plan and Regimen Coding Alignment
We require treatment plan documentation to explicitly reference each drug billed, with protocol name, cycle number, and clinical indication.
Drug Waste Allowance Governance
Certified oncology coders calculate waste allowances specific to the payer and drug class, capping submissions at plan maximums.
Multi-Modality Concurrent Care Documentation
When chemotherapy and radiation therapy occur within 7 days, our system requires separate treatment plans and verification of payer policy governing concurrent billing.
High-Cost Drug Administration Coding
For biologics, monoclonal antibodies, and specialty chemotherapy infusions exceeding $5K per administration, we apply secondary validation.
Recoupment Prevention and Audit Readiness
Our system maintains a 3-year archive of all treatment plans, infusion logs, waste calculations, and claim submissions for regulatory support.
Revenue Exposure Categories Addressed
- Infusion code denial from undocumented or mismatched administration time intervals
- Drug waste recoupment from overbilling allowance limits specific to payer and drug class
- Concurrent modality bundling from missing documentation supporting separate billing
- Treatment plan non-alignment creating claim rejections for missing drug protocols
- High-cost drug administration coding errors on specialty infusions and biologics